Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection

New England Journal of Medicine

Volumn 373, Issue 27, 2015, Pages 2599-2607

  Feld, J J ^a   Jacobson, I M ^a   Hode, C ^a   Asselah, T ^b   Ruane, P J ^b   Gruener, N ^a   Abergel, A ^a   Mangia, A ^b   Lai, C L ^b   Chan, H L Y ^a   Mazzotta, F ^a   Moreno, C ^a   Yoshida, E ^a   Shafran, S D ^b   Towner, W J ^b   Tran, T T ^a   McNally, J ^a   Osinusi, A ^a   Svarovskaia, E ^a   Zhu, Y ^a   Brainard, D M ^a   McHutchison, J G ^b   Agarwal, K ^b   Zeuzem, S ^a   more..

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NONSTRUCTURAL PROTEIN 5A; PLACEBO; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; SOFOSBUVIR; VELPATASVIR; VIRAL PROTEIN;

ABNORMAL LABORATORY RESULT; ANTIVIRAL RESISTANCE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLACK PERSON; CHRONIC HEPATITIS C; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; INSOMNIA; LYMPHOCYTE COUNT; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTICENTER STUDY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RECURRENCE; SOFOSBUVIR; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84952883325     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1512610     Document Type: Article

References (18)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
4. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.
5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128.
6. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C (http//www .hcvguidelines .org).
7. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
8. Muir AJ, Naggie S. Hepatitis C virus treatment: is it possible to cure all hepatitis C virus patients? Clin Gastroenterol Hepatol 2015; 13: 2166-72.
9. Cheng G, Yu M, Peng B, et al. GS-5816 A second generation HCV NS5A inhibitor with potent antiviral activity, board genotypic coverage and a high resistance barrier. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver, Amsterdam, April 24-28, 2013. abstract.
10. Doehle B, Dvory-Sobol H, Hebner C, et al. Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1-3 NS5A resistanceassociated variants. Presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1-5, 2013. abstract.
11. Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 2015; 22:1011-9.
12. Everson GT Towner WJ Davis MN et al, Sofosbuvir with velpatasvir in treatment-nae non-cirrhotic patients with genotype, 1-6 hepatitis C virus infection: a randomized trial. Ann Intern Med, 2015, November, 10, Epub ahead of print
13. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir-velpatasvir combination therapy for treatment-experienced patients with genotype 1 and 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015 November 10 (Epub ahead of print).
14. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17.
15. Curry MP, OLeary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-28.
16. Weins BL, Lystig TC, Berry SM. Recent statistical contributions to medical device development. Ther Innov Reg Sci 2014; 48: 90-7.
17. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: Suppl: S45-S57.
18. Wendt A, Adhoute X, Castellani P, et al. Chronic hepatitis C: future treatment. Clin Pharmacol 2014; 6: 1-17.